Results 101 to 110 of about 44,923 (207)

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

International Journal of Cancer, Volume 159, Issue 4, Page 936-950, 15 August 2026.
What's new? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar, Marco Strecker, Thomas Wartmann, Wenjie Shi, Frederike Stelter, Maximilian Doelling, Mihailo Andric, Or Kakhlon, Christian Täger, Denny Schanze, Michael Linnebacher, Michael Naumann, Daniel E. Stange, Dörthe Jechorek, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Can Response Outcomes Predict Survival in Paediatric Patients Receiving Treatment for Relapsed and Refractory Rhabdomyosarcoma? Results From the Living‐REFoRMS Systematic Review

International Journal of Cancer, Volume 159, Issue 4, Page 997-1004, 15 August 2026.
Although existing research suggests a limited relationship between survival outcomes and radiological response rates in children with newly diagnosed rhabdomyosarcoma, there is little evidence in the relapsed/refractory setting. Using aggregate data collected from the Living‐REFoRMS dataset of early‐phase trials, the authors established that ...
Preethi Muthukumar, Lucy Shepherd, Sumayya Anwer, Connor Evans, Jessica E. Morgan   +4 more
wiley   +1 more source

Protective effects of N-acetylcysteine against irinotecan – induced pulmonary toxicity in female albino rats

Zanco Journal of Medical Sciences
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a deadly lung illness characterized by progressive lung fibrosis and deteriorating lung function, with the uncertain origin and few therapeutic options. Chemotherapy such as Irinotecan (IRI)
Hawrin Burhan Khudhur, Ansam Al-Hassani
doaj   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo   +7 more
wiley   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, Volume 6, Issue 8, August 2026.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, Volume 159, Issue 3, Page 719-728, 1 August 2026.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

Deciphering the Formulation‐Dependent Neurotoxicity of Irinotecan: An Integrated Pharmacovigilance and Mechanistic Study

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Overall workflow of the study, from computational toxicology screening and FAERS‐based data mining to mechanistic prediction of neurotoxicity of irinotecan. ABSTRACT Irinotecan is a key chemotherapeutic agent, but its neurotoxicity limits its utility.
Cheng Shen, Wei Ma, Jing Lu, Yongbo Tang, Wei Cao   +4 more
wiley   +1 more source

Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

Cancer Medicine
Introduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin, Shuting Liu, Hongfei Jiang, Shasha Wang, Yixin Duan   +4 more
doaj   +1 more source